Chief Endocrinologist · Crinetics Pharmaceuticals, Inc. (CRNX)

Alan Krasner

FY2023 is the first fiscal year CompBrief holds for Alan Krasner as a named executive officer of Crinetics Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,162,574

Salary $459,692Stock awards $382,980

5th of 7 named executive officers at Crinetics Pharmaceuticals by FY2023 total.

7 named officers on file for Crinetics Pharmaceuticals, FY2023

Alan Krasner’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • CRNX’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Crinetics Pharmaceuticals’s whole pay program stands against its peers

  • Crinetics Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CRNX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2024 (DEF 14A).

Free

Get Alan Krasner’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Alan Krasner compensation by year

Crinetics Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Crinetics Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$459,692
Bonus$0
Stock awards$382,980
Option awards$1,125,670
Non-equity incentive$191,232
Pension and deferred compensation$0
All other$3,000
Total$2,162,574

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Crinetics Pharmaceuticals, Inc. DEF 14A filed April 25, 2024, accession 0000950170-24-048438, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Crinetics Pharmaceuticals, Inc. filed document, accession 0000950170-24-048438. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2024.

Crinetics Pharmaceuticals’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
R. Scott StruthersPresident and Chief Executive Officer$5,747,994
Marc WilsonFormer Chief Financial Officer$2,513,495
Stephen BetzChief Scientific Officer$2,496,868
Jeff KnightChief Operating Officer$2,362,362
Alan Krasner · this pageChief Endocrinologist$2,162,574
James HassardChief Commercial Officer$1,705,607
Dana PizzutiChief Medical Officer$1,102,038

The full Crinetics Pharmaceuticals compensation record

free company brief

This page is one person within Crinetics Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Crinetics Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Alan Krasner's compensation dossier · One-time report. No refunds.